Member access

4-Traders Homepage  >  Shares  >  Toronto Stock Exchange  >  Cardiome Pharma Corp.    COM   CA14159U3010

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
04/08/2015 04/09/2015 04/10/2015 04/13/2015 04/14/2015 Date
11.6 11.92 12.19 11.91 11.9 Last
4599 3743 3952 1065 2800 Volume
-2.36% +2.76% +2.27% -2.30% -0.08% Change
Financials ( CAD)
Sales 2015 42,7 M
EBIT 2015 -14,3 M
Net income 2015 -5,57 M
Debt 2015 -
Yield 2015 -
Sales 2016 54,8 M
EBIT 2016 -7,37 M
Net income 2016 0,43 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 4,54x
Capi. / Sales 2016 3,54x
Capitalization 194 M
More Financials
Company
Cardiome Pharma Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of new therapies that will improve the health of patients around the world.Its product BrinavessTM approved in Europe and other territories for the rapid conversion of recent... 
Sector
Pharmaceuticals
Calendar
05/11Earnings Release
More about the company
Surperformance© ratings of Cardiome Pharma Corp.
Trading Rating : Investor Rating :
More Ratings
Latest news on CARDIOME PHARMA CORP.
04/09 CARDIOME PHARMA : Receives BRINAVESS Reimbursement Approval From Belgian Authori..
03/12 CARDIOME PHARMA : reports fourth quarter and full year 2014 financial results
03/05 CARDIOME PHARMA : to Hold Fourth Quarter and Full Year 2014 Financial Results Co..
2014 CARDIOME PHARMA : Enters Development And Commercialization Agreement With Edding..
2014 CARDIOME PHARMA : Enters Development and Commercialization Agreement with Edding..
2014 CARDIOME PHARMA : Enters Commercialization Agreement With Aspen For Brinavess In..
2014 CARDIOME PHARMA : Enters Commercialization Agreement with Aspen for BRINAVESS® i..
2014 CARDIOME PHARMA : Submits BRINAVESS® Reimbursement Dossier to Italian Authoritie..
More news
Sector news : Biopharmaceuticals
12:47p MERCK : drug Keytruda effective against 3 cancers (Studies)
12:46p MERCK : Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 T..
12:45p MERCK : Early Findings with Pembrolizumab, Merck's Investigational Anti-PD-1 The..
More sector news : Biopharmaceuticals
News from SeekingAlpha
03/12 Cardiome Pharma's (CRME) CEO William Hunter on Q4 2014 Results - Earnings Cal..
03/12 Cardiome Pharma misses by $0.25, misses on revenue
03/11 Notable earnings before Thursday?s open


Comments 
Advertisement
Chart CARDIOME PHARMA CORP.
Duration : Period :
Cardiome Pharma Corp. Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF